|Bid||19.33 x 1000|
|Ask||19.35 x 800|
|Day's Range||19.22 - 19.90|
|52 Week Range||9.04 - 28.75|
|Beta (3Y Monthly)||2.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.17|
SAN FRANCISCO , Nov. 21, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Shelly Guyer , chief financial officer of Invitae, will participate ...
PHILADELPHIA, Nov. 15, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced Invitae Discover, a clinical research platform that leverages biometric data available through Apple Watch to provide better understanding of the genetic causes of disease. The first study on the platform will evaluate genetics in cardiovascular disease and was announced in conjunction with the American Heart Association's Scientific Sessions where researchers are presenting data on genetic screening in familial hypercholesterolemia.
The two big rounds were a $400 million round for a Chinese Tesla competitor whose U.S. operations are in Mountain View and a $100 million round for San Francisco-based food delivery unicorn DoorDash.
Invitae's third acquisition in four months is indicative of consolidation in the genetic testing arena.
SAN FRANCISCO, Nov. 11, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Clear Genetics, a leading developer of software for providing genetic services at scale. Using intuitive chatbots, Clear Genetics equips patients with actionable information throughout the genetic testing process and provides guidance for understanding test results. The acquisition will further expand Invitae's ability to scale and deliver genetic information as a part of routine medical care.
BURLINGTON, Vt., Nov. 8, 2019 /PRNewswire/ -- The University of Vermont Health Network has begun a pilot project to offer Genomic DNA Testing to patients as part of their clinical care. The pilot program is the beginning of an effort to increase the integration of genetic disease risks into routine medical care, which holds promise for providing Vermonters with valuable information to guide their health decisions. "Our overall health and longevity are determined about 30 percent by genetics," said Debra Leonard, MD, PhD, Chair, Pathology and Laboratory Medicine.
Biotechnology stocks have been outperforming over the past month, but ETF investors seem disinterested and are even trimming exposure to this sector. In a weekly update on the flow of money in and out of stock funds, PiperJaffray analyst Christopher J. Raymond pointed out that investors pulled a net $99 million out of healthcare and biotech-related funds in the one-week period ended on Wednesday, Barron's reports. The latest redemptions seems surprising given the recent outperformance of the biotechnology sector.
Invitae (NVTA) delivered earnings and revenue surprises of -32.69% and 2.75%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Increased quarterly revenue by 51% and volume by 65% year-over-year -- -- Now in network with Cigna, all major payers with approximately 295 million covered lives -- -- Hosting conference call and webcast ...
SALT LAKE CITY , Nov. 5, 2019 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting research this week at the National Society of Genetic ...
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
SAN FRANCISCO, Oct. 23, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 9085356.
On Oct. 11, a short seller article published on Seeking Alpha accused InVitae of being the next Theranos. The short seller implied InVitae’s strong revenue growth may have been obtained via fraudulent measures and InVitae is burning through cash at an irresponsible level. On Oct. 13, Capital Markets Laboratories CEO Ophir Gottlieb published a rebuttal to the Seeking Alpha story.
-- Advances in classification, new approaches to genetics in cancer and implications of primary and secondary findings for clinical care among wide-ranging data presentations -- HOUSTON , Oct. 17, 2019 ...
After dropping notably in the morning, stocks reversed and closed higher on the day. It leaves investors wondering what's next for the market. In the meantime, here are a few top stock trades. Top Stock Trades for Tomorrow 1: NvidiaNvidia (NASDAQ:NVDA) stock held the $172.50 level for four consecutive sessions. It was an impressive couple of days as bulls refused to break. On Wednesday, shares caught a boost after Goldman Sachs analysts took their price target from $179 to $192. InvestorPlace - Stock Market News, Stock Advice & Trading TipsAs shares reclaim the 20-day moving average, traders are shifting their outlook higher in the short term. Look to see if the stock can get back to $185, recent resistance earlier this month. Above it puts the high at $188.40 on the table, which comes into play near the 61.8% retracement. On the downside, watch $172.50. Below could send shares to the 50-day and possibly the 200-day moving average. Top Stock Trades for Tomorrow 2: Match GroupMatch Group (NASDAQ:MTCH) took a hit on Wednesday, as cracks start to show up on the chart. For now, shares are holding onto the 61.8% retracement. Below it will put Wednesday's lows on the table. The $65 level has been decent support, while the 200-day moving average is near $64 and the 50% retracement is near $63. On a rebound, see if MTCH stock can get back to $80. Top Stock Trades for Tomorrow 3: InvitaeI love Invitae (NASDAQ:NVTA) for the long term, but it would be foolish to ignore the charts. Invitae is taking out this month's low and falling below the 200-day moving average.Should shares continue lower, look for the 50% retracement just below $19. If it fails as support, look for a potential test of the May lows, with support in the low-$17s. At that point though, bulls may as well just ask for a January gap-fill and test of the 38.2% near $16.50. On the upside, NVTA needs too reclaim the 200-day moving average, as well as the $22 level, which is acting as short-term resistance. Top Stock Trades for Tomorrow 4: CintasCintas (NASDAQ:CTAS) has seen a widening range (blue lines) since popping higher in July. On Wednesday, shares jumped on better-than-expected earnings results. Thanks to its rally, CTAS is reclaiming the 50-day moving average and is approaching resistance at $270. Over $270 puts the 52-week high of $270.36 on the table, as well as a possible run to $276, which is recent trend resistance. Top Stock Trades for Tomorrow 5: ServiceNowServiceNow (NASDAQ:NOW) has been frustrating investors lately, but pleasing traders as it bounces between $250 range support and $270 range resistance. The setup is simple: traders can go long near $250 support and sell near $270 resistance. If shares break down below support, see if the 200-day supports it, along with the 61.8% retracement near $243.75. Over $270 -- which is also roughly the 78.6% retracement -- and a move toward $290 may be under way. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long NVTA and NVDA. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 High-Yield Dividend Stocks Set for Growth * 10 Wonderful Companies Whose Valuations Aren't Quite Fair * 5 Stocks to Buy That Could Double in 2020 The post 5 Top Stock Trades for Thursday: NVDA, MTCH, NVTA appeared first on InvestorPlace.
SAN FRANCISCO, Sept. 9, 2019 /PRNewswire/ -- Invitae (NVTA), a leading medical genetics company, today announced the availability of Detect Hereditary Pancreatic Cancer, a testing program that offers no-charge genetic testing and counseling to patients with pancreatic cancer. Genetic testing is recommended by clinicians for all pancreatic cancer patients to guide treatment choices and evaluate eligibility for clinical trials.